• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Amyloid pathology may be detected decades prior to Alzheimer’s diagnosis

byJohn PrendergassandPriyanka Vedak
May 19, 2015
in Chronic Disease, Neurology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. In this study, the presence of amyloid in patients without dementia was associated with age, APOE genotype, and presence of cognitive impairment.

2. In this study, when the prevalence of age-related and APOE genotype-specific amyloid positivity in individuals with normal cognition was compared to the age-related and APOE genotype-specific prevalence of Alzheimer’s disease type dementia, an association was detected with a time lag of about 20 to 30 years.

Evidence Rating Level: 2 (Good)

Study Rundown: Alzheimer’s disease, a debilitating and progressive mental illness, affects millions across the globe. A key marker to the diagnosis of Alzheimer’s disease (AD) is the presence of amyloid-β-aggregation in the brain. While the discovery of this pathology is often made well after the onset of symptoms, such a pathological change can be present 20 years prior to diagnosis. Prior studies have analyzed, with significant variability, the prevalence of such pathology in pre-demented patients.

This study evaluated the prevalence of amyloid-β-aggregate biomarkers in patients with normal cognition, subjective cognitive impairment (SCI), and mild cognitive impairment (MCI) and correlated it with known AD risk factors. This study found that the previously identified risk factors for AD of age and APOE genotype, were the same risk factors that were noted in this study to be associated with amyloid deposition in individuals with normal cognition, thus supporting the role of amyloid deposition as a marker of early AD. When the prevalence of age-related and APOE genotype-specific amyloid positivity in individuals with normal cognition was compared to the age-related and APOE genotype-specific prevalence of Alzheimer’s disease type dementia, an association was detected with a time lag of about 20 to 30 years. While strengths of this study include a participant-level analysis as well as a large number of studies evaluated, it may be weakened by a self-selection bias due to voluntary recruitment strategies. Based on these study results, it may soon be possible to identify early stage Alzheimer’s disease years before cognitive and behavioral symptoms emerge. Further research is required to evaluate risk assessment measures as well as the potential for anti-amyloid-β-therapies.

Click to read the study, published today in JAMA

RELATED REPORTS

The Scan by 2 Minute Medicine®: Versatile Ozempic, Healthcare Reform, Unlocking the Brain, and Chickens and the Next Pandemic:

Caregivers of people with dementia may benefit from online decision aid when managing firearm access

High-sugar dietary pattern associated with increased risk of dementia

Click to read the accompanying editorial, published today in JAMA

Relevant Reading: Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging and the Alzheimer’s Association workgroup

In-Depth [meta-analysis]: This meta-analysis included data from 2914 (38%) patients with normal cognition, 697 (9%) with SCI, and 3972 (52%) with MCI. Amyloid positivity was more common in patients with MCI compared with participants with normal cognition (mean difference 25%; 95%CI 22% to 28%; p < 0.001) or SCI (mean difference 23%; 95%CI 14% to 32%; p < 0.001). Across groups, amyloid deposition increased with age and APOE-ε4 carriers had a 10%-40% higher absolute prevalence than non-carriers. APOE genotype was associated with the age of onset of amyloid positivity, with the earliest amyloid deposition detected at 40 years for ε4ε4 carriers and the latest detected at 95 years for ε2ε3. Amyloid positivity when assessed in both an age-related and APOE genotype-specific manner and compared to AD risk in an age-related and APOE genotype-specific manner, respectively, revealed a time lag of about 20 to 30 years.

Image: CC/Wiki

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Alzheimer’s diseaseamyloid
Previous Post

Lipid lowering drugs in the elderly may decrease stroke risk

Next Post

Stereotactic radiosurgery may effectively treat facial nerve schwannoma

RelatedReports

The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Versatile Ozempic, Healthcare Reform, Unlocking the Brain, and Chickens and the Next Pandemic:

January 7, 2025
Public Health

Caregivers of people with dementia may benefit from online decision aid when managing firearm access

October 22, 2024
Neurology

High-sugar dietary pattern associated with increased risk of dementia

July 25, 2024
Amyloid may cause distant cerebral hypometabolism in Alzheimer’s
Chronic Disease

APOE3 Christchurch heterozygosity may delay cognitive impairment in Alzheimer’s disease

June 25, 2024
Next Post
Stereotactic radiosurgery may effectively treat facial nerve schwannoma

Stereotactic radiosurgery may effectively treat facial nerve schwannoma

High-flow oxygen therapy as effective as BiPAP in preventing reintubation

High-flow oxygen therapy as effective as BiPAP in preventing reintubation

Intravenous contrast may not increase risk of acute kidney injury

Drug ameliorates effects of chronic kidney disease by targeting cell cytoskeleton [PreClinical]

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early screening for emotional and cognitive issues may improve psychiatric outcomes for stroke patients
  • Artificial intelligence may assist in early detection of decreased ejection fraction on echocardiograms
  • #VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.